Real-World Spanish Experience with Voclosporin in the Management of Lupus Nephritis (LUPUS 2026) - Feb 17, 2026 - Abstract #PO:11:296; 24; Pres time: Mar 6, 2026; 07:30 AM - 07:30 PM; Location: Poster Area; "One death occurred, attributed to cardiac causes.Adverse events were reported in five patients: gingival hyperplasia (n=1*), renal function deterioration (n=2, both with baseline eGFR <45 mL/min), upper respiratory tract infection (n=1*), and hirsutism (n=1). Two of these events (*) led to permanent treatment discontinuation.Among the 13 switch cases, 5 reported improved tolerability compared with their previous CNI (less tremor, alopecia, diarrhea, and palpitations).Abstract PO:11:296 Table 1 Conclusions In this real-world Spanish cohort, voclosporin appeared to demonstrate efficacy and safety in the treatment of lupus nephritis."
Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis
|
|
Ana Huerta Arroyo; Marc Xipell; Helena Marco; Irene Agraz; Raul Fernandez-Prado; Vanessa Lopes; Iara Da Silva; Elena Monfá; Fayna Gonzalez; Ana Pareja; Juan Martin; Xoana Barrios; Tania Linares; Carmen Cobelo; Maria Carmen Prados; M Loreto Fernandez; Cristina Vega; Jose Ivorra; Maria Galindo; Andres Gonzalez; Vanesa Calvo; Jose Luis Callejas; Enrique Morales
|